James Hamrick, Chair of Precision Oncology Alliance at Caris Life Sciences, shared on LinkedIn:
“When a conversation makes it into the New England Journal of Medicine it’s a signal: this matters.
Proud to share that our team at Caris Life Sciences contributed to this important dialogue with a letter to the editor now published in NEJM. This recognition reflects our commitment to scientific rigor and real-time collaboration with our POA partners to advance research to benefit patients.”
More posts featuring Caris Life Sciences on OncoDaily.